Celldex Therapeutics (CLDX) Other Non-Current Assets (2016 - 2025)
Historic Other Non-Current Assets for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $9.4 million.
- Celldex Therapeutics' Other Non-Current Assets fell 392.94% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 392.94%. This contributed to the annual value of $9.7 million for FY2024, which is 900934.58% up from last year.
- Per Celldex Therapeutics' latest filing, its Other Non-Current Assets stood at $9.4 million for Q3 2025, which was down 392.94% from $9.3 million recorded in Q2 2025.
- Over the past 5 years, Celldex Therapeutics' Other Non-Current Assets peaked at $10.4 million during Q1 2025, and registered a low of $41000.0 during Q1 2021.
- Its 5-year average for Other Non-Current Assets is $2.6 million, with a median of $107000.0 in 2023.
- Data for Celldex Therapeutics' Other Non-Current Assets shows a peak YoY increase of 962803.74% (in 2025) and a maximum YoY decrease of 392.94% (in 2025) over the last 5 years.
- Over the past 5 years, Celldex Therapeutics' Other Non-Current Assets (Quarter) stood at $104000.0 in 2021, then changed by 0.0% to $104000.0 in 2022, then increased by 2.88% to $107000.0 in 2023, then soared by 9009.35% to $9.7 million in 2024, then dropped by 3.93% to $9.4 million in 2025.
- Its Other Non-Current Assets was $9.4 million in Q3 2025, compared to $9.3 million in Q2 2025 and $10.4 million in Q1 2025.